Abstract This is an exciting time for patient-centered care. The window of opportunity appears to be open for the medical culture to accept the importance of the patients' values, goals and preferences in guiding medical decisions. Heart failure guidelines are changing to include language around shared decision making for major procedures and end-of-life care. However, while the cultural norms appear to be moving in this direction, the science regarding how to best deliver patient centered care (basic, clinical, delivery, and policy) is still developing. This article will provide a broad overview of the science of decision making in advanced heart failure using a translational science framework.
The basic science of decision making -T1
Decision making theory
The classical decision-making theory is Expected Utility Theory (EUT), proposed by the economist Ward Edwards in 1954 [3] . This theory assumes that humans make decisions rationally by acquiring information, determining the possible outcomes of a choice, and choosing whichever option maximizes gains. Much of the field of medical decision-making continues to rely on this idea that if properly informed, patients will think rationally and make optimal decisions aligned with their values and preferences [4] . However, modern theories of decision science have shown that, when it comes to real-world decision making, EUT is inaccurate [5] . First, there is the simple problem of numeracy -the idea that people often do not know or understand how to interpret numbers [6] . Second, the field of behavioral economics led by Dan Kahneman and Amos Tversky has demonstrated that people often deviate from rational decision making in predictable ways [5] . Third, recent research has highlighted the unpredictable effects that emotion can play on decision making [7, 8] .
Numeracy
Those with low numeracy often have difficulty understanding and processing numerical risk/benefit information frequently presented in the medical literature. A well-known problem is confusing the difference between relative and absolute risk thus drastically overestimating both the risks and benefits [9] . Those who are low in numeracy are more prone to experience confusion or bias (discussed below) when numerical information is not presented in a balanced way [10] . While informing patients about risks and benefits is necessary, the way that this information is presented is important to assure that consumers of the information interpret them correctly. Research suggests that people wishing to present statistics should present them in both a qualitative and quantitative way using diagrams or pictures so that people with differing levels of numeracy can understand the information presented [11] .
Emotion and heuristics
Emotions and heuristics -short cuts our brains use to make decisions quickly -can also influence our decisions in ways that deviate from EUT. Affect heuristic for example, is a wellknown cognitive bias showing that a person's negative or positive mood can influence how they make a decision [12] . In an early study by Khaneman and Tversky, affect was shown to shape perceptions of risks. In this study, participants read articles designed to induce a positive or negative affect and then were asked to estimate the risk of a number of fatalities. Those who had read negative articles were more likely to predict higher rates of fatalities than those who read the positive article. In advanced heart failure, we qualitatively found a very strong influence of emotion in patients' decisions to pursue a ventricular assist devices for destination therapy [13] .
Kahneman and Tversky developed the dual-process theory of decision-making to expand upon EUT and try explain the effects of cognitive bias [5] . This theory defines two operating systems in decision-making: 1) the unconscious, rapid, automatic system (system 1); and 2) the conscious, effortful reflective system (system 2). System 1 processes information unconsciously, is not affected by complexity, and has a seemingly unlimited capacity to make decisions, but it is also be more susceptible to cognitive bias and emotion. In contrast, system 2 is deliberate and weighs the cognitive information involved in the decision making. System 2 requires effort and humans tend to revert to system one unless they are actively engaging their cognitive decision making processes. While in reality, both systems work simultaneously and the dichotomy is largely artificial, it is a helpful way to think about different cognitive pathways. George Lowenstein has demonstrated that people in an emotional state cannot predict how they themselves would feel in a less emotional state -termed the Bhot/cold empathy gap.^ [8] Patients with advanced heart failure may feel a number of emotions including depression, anxiety, worry, fear, sadness, and anger especially if the decision deals with mortality as is the case with things like defibrillators and ventricular assist devices.
More recently, scholars have expanded upon the dual process theory arguing that it is falsely dichotomous. The Fuzzy Trace Theory (FTT) was developed by Reyna et al., and states that when making a decision people create a Bgist^represen-tation of the information, a subjective interpretation based on emotion, education, culture, experience, values, worldview, and age [14, 15] . This Bgist,^is different than the Bverbatim,î nformation presented, which is often precise quantitative information. Creating a gist meaning requires a complex thought process that includes both intuitive and cognitive information. For example, if someone is told that their risk of suffering a heart attack is 20%, their crudest gist interpretation of the information may be Bmy risk is high,^prompting them to engage in actions to decrease their risk.
Basic science agenda
Clearly, decision-making for patients is much more than a process of presenting risks and benefits as would be predicted by EUT. Rather, the Dual Process and Fuzzy Trace theories help us understand that perhaps a new approach needs to be considered with medical decision making. The research opportunities in the basic science of decision making are abundant. The clinical/applied research of decision making -T2 Despite the challenges above, patients, caregivers, and clinicians make challenging decisions in advanced heart failure daily. Patients with heart failure face a multitude of decisions including which medications to take and whether to get an ICD, a left ventricular assist device, or a heart transplant. Current evidence suggests that a large proportion of patients have a poor understanding of the risks and benefits of these therapies [13, [16] [17] [18] . Also, many patients are not involved in their decision-making process as much as they'd like to be [19] . Seemingly simple decisions about whether to try a different medicine, such as Entresto (valsartan/sacubitril), are fraught with considerations of risks, benefits, and costs [20] . Perhaps most notably, patients with advanced heart failure often have to make incredibly complex decisions about invasive therapies that have the potential to prolong life, but also have associated morbidity and mortality. It is understandably difficult to cognitively process these issues when the emotional concepts of death and dying hang in the balance. One strategy to assist patients in making decisions is shared decision making (SDM). A commonly accepted definition of the SDM includes four components: 1) at least two participants, the clinician and patient be involved; 2) both parties share information; 3) both parties take steps to build a consensus about the preferred treatment; and 4) an agreement is reached on the treatment to implement. Perhaps a better definition comes from 1985 and termed it BA meeting between experts.^ [21] This definition very simply highlights one of the most important concepts of SDM, notably that the patient has expertise. While the patient's expertise may not be medical, the patient is an expert on their goals, values, preferences, and life-circumstances. These are all things a clinician needs to understand before recommending a therapy. Research on optimal strategies to achieve SDM has included work in patient decision aids (PtDAs), decision coaching, and communication interventions.
T1 -TranslaƟon to Humans

Decision aids
The International Patient Decision Aid Standards (IPDAS) were established in 2003 to enhance quality and effectiveness of PtDAs by establishing a framework for content, development, implementation, and evaluation [22] . PtDAs are highly efficacious -a Cochrane review of 115 randomized trials demonstrated that they improve knowledge, satisfaction, patient/provider communication, increase patient involvement in decision making, and reduce patient decisional conflict and regret [23] .
Within the field of heart failure, there are an increasing number of available PtDAs. Recent work has been done to develop PtDAs for patients considering getting a leftventricular assist device (LVAD) [1] , an implantable cardioverter defibrillator (ICD), replacement of an ICD, and cardiac resynchronization therapy (CRT). There are also additional PtDAs in cardiology for patients considering surgical aortic valve replacement (SAVR), coronary angiogram, coronary artery bypass grafting surgery (CABG), and various therapies for atrial fibrillation (AF) [24] .
Communication and decision coaching
Beyond PtDAs, there is also ongoing work to enhance shared decision making through improved communication. In heart failure, evidence-based communication interventions are sparse. Trials such as the WISDOM trial aim to improve communication between the provider and the patient/caregiver with the goal of increasing conversations about deactivating ICDs, increasing ICD deactivations at the end of life, and improving psychological outcomes of bereaved caregivers [25] . The challenge with communication interventions is convincing clinicians that they need to improve their communication skills. In particular, many clinicians already believe that they are doing shared decision making [26] . Similarly, a strategy of decision coaching has been adopted in other settingsincluding cancer -and utilizes people trained to coach patients in discussing major decisions with their clinicians and prepare them for shared decision making [27] . To our knowledge, neither of these strategies have been widely attempted in advanced heart failure.
Delivery and implementation science -T3
The focus of T3 science is translating the evidence to practice. This type of health delivery science engages the complexity involved in our health care system. If T2 is about Befficacy^, then T3 is about real-world Beffectiveness^and implementation. As mentioned above, shared decision making in general and PtDAs in particular have a strong and growing base of evidence, but largely in controlled efficacy settings. They remain largely unimplemented in the real world. A recent systematic review of PtDA implementation identified a host of logistical barriers, including clinicians' perception of time necessary to use PtDAs, lack of reimbursement, and a perception that the PtDAs themselves were biased either for or against a therapy. Perceived bias inherent in the PtDAs themselves [28] . The authors of this systematic review argued that the research should move beyond barriers and facilitators and begin to use frameworks to advance the science of implementation. To illuminate some of the work in this space, we will discuss our ongoing work attempting to implement decision aids into practice.
Implantable defibrillators
We have developed and studied decision aids for implantable defibrillators [29, 30] . One collaborative aimed to implement the primary prevention ICD decision aid as part of a large implementation project funded by the centers for Medicare and Medicaid across 17 health systems. The strategy this project used was a paid health coach as the agent of delivery of the PtDAs. Ultimately, this implementation was unsuccessful due to the fact that none of the health systems continued funding the health coaches independently when the CMMI funding ended. We are in the process of qualitatively studying this natural implementation experiment. While official, peerreviewed results are forth coming, it appears there were multiple challenges hindering successful implementation including health coaches working across multiple conditions in multiple clinics and a lack of clinical champions. The most successful site appeared to achieve clinician engagement at multiple levels but even this site did not continue the program when the funding ended. In our next scope of work, we are working directly with clinics to help each clinic develop a tailored strategy of decision aid implementation that fits their local context with the longer term goal of creating a sustainable implementation when the funding ends.
Left ventricular assist devices
Today, patients with advanced heart failure may be eligible for an increased number of treatment options. Only a small percentage will be fortunate enough to receive a heart transplant while many others now have the option to live out the remainder of their lives with a destination therapy left ventricular assist device (DT-LVAD). For eligible patients who decide not to get a DT LVAD, 2-year survival is less than 1 out of 10; with a DT LVAD, 2-year survival is nearly 7 out of 10 [31] . However, significant risks accompany a DT LVAD, including stroke (1 out of 10), serious infection (3 out of 10), severe bleeding (2 out of 10), and reoperation (1 out of 10) [32] . Further, the DT LVAD causes major lifestyle changes for patients and caregivers, including the need for patients to be connected to electricity at all times [33] .Dying with a DT LVAD creates even more confusion for caregivers who were uninformed and consequently unprepared for the events surrounding a dying process including deactivation in particular [34] .
Following the Ottawa Decision Support Framework, we developed an 8-page paper and a 27-min video based decision aid. The decision aid addressed several novel features based on our needs assessment including emotion (fear of dying), patient narratives, and caregiver perspectives [35] . The full details of the development have been described elsewhere [35] and the decision aids are freely available online.(www. patientdecisionaid.org) We are currently conducting a combined type II, effectiveness/implementation hybrid trial [36] , to implement a DT LVAD decision aid at six heart failure programs across the United States. To simultaneously test effectiveness and implementation, we conducted a steppedwedge design where the PtDA was implemented sequentially across the six sites [37] . At the time of the implementation, the team conducted an implementation intervention consisting of a 1-h grand rounds on the overall topic for anyone at the institution, a 1-h presentation of the video along with communication training to the clinical team directly involved in the care of these patients, and a discussion with the site-PI and direct staff regarding how they will change their current practice to implement the decision aid. We are using the RE-AIM framework for evaluating implementation interventions to organize the overall evaluation strategy studying both real world effectiveness and factors influencing implementation [38] . The trial is currently enrolling patients and the results will be available in late 2017.
Multiple other decisions in advanced heart failure are ripe for formal shared decision making interventions including inotropic support, transfemoral aortic valve replacement, and ICD deactivation at the end-of-life. Not to mention the many, chronic, day-to-day decisions related to medication and lifestyle modifications. The multitude of potential decisions will almost certainly increase as technologies and therapies continue to expand. The challenge of implementing shared decision making into complicated clinical settings will remain an ongoing challenge.
Population and policy -T4
As advances in the science of decision making continues, there is also a growing movement at the population and policy levels to involve patients more directly in their decision making. Some have argued that healthcare payers should pay for the use of PtDAs in clinical practice as these tools may actually simultaneously increase quality by improving patients' understanding and involvement in their decisions and decrease costs as better informed patients often choose less invasive options [39] . While this cost saving effect is neither the primary aim of shared decision making nor proven, it has had the effect of raising the attention of payers and policy makers alike.
Legal and regulatory
Given the increasing primacy placed on patient-centered care, it should come as no surprise that shared decision making has become a major issue in state healthcare laws. Currently seven states (Maine, Massachusetts, Minnesota, Oregon, Vermont, Washington, and Wisconsin) have some sort of promotion of SDM in clinical practice [40] . Many do this through revised statues lowering a physician's exposure to malpractice litigation if there is documentation of use of a decision aid. Likewise, the Food and Drug Administration (FDA) has been increasing patient involvement in the drug and device approval process. Through the Patient Preference Initiative [2] . In 2015, they formalized this process announcing the Patient Engagement Advisory Committee with a stated purpose that BThe Committee will provide relevant skills and perspectives, in order to improve communication of benefits, risks, clinical outcomes, and increase integration of patient perspectives into the regulatory process for medical devices.^ [41] Payment Likewise, payment reform is catching on. There have been two recent decisions by the Centers for Medicare and Medicaid Services (CMS) that require SDM for payment. The first was a decision about left atrial appendage closure (LAAC) therapy in non-valvular atrial fibrillation (NVAF) [42] and the second was related to the left ventricular assist device -see Box [43] . Given changes with MACRA and the ongoing push towards more patient involvement in their health care, these policies are almost certain to continue.
Box: Language in Medicare Coverage Criteria Endorsing Shared Decision Making in Heart Diseases Non-valvular atrial fibrillation: BA formal shared decision-making interaction between the patient and provider using an evidence-based decision tool on anticoagulation in patients with NVAF must occur prior to LAAC, must be documented in the medical records, must include a discussion of the benefits and harms, must document an appropriate rationale to seek a non-pharmacologic alternative to anticoagulants, taking into account the safety and effectiveness of the device compared to anticoagulants, and have, after being informed of the reported risks of LAAC and reasonable alternative management strategies, given informed consent.L eft Ventricular Assist Devices: BCollectively, the team must ensure that patients and caregivers have the knowledge and support necessary to participate in shared decision making and to provide appropriate informed consent.Ĉ onclusions There are two big lessons from a survey of the science of decision making in advanced heart failure. The first lesson from the overview of the science above is that it is not linear. While it would make sense for the formative T1 work to occur before the T4 work, this is not the reality. The second lesson from the discussion above is the increasing societal demand and a changing norm around the importance of patient involvement and patient-centered care.
